Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
263 Leser
Artikel bewerten:
(1)

Pain Management Devices Market to Hit USD 5,835.8 Million by 2029 with 9.1% CAGR | MarketsandMarkets

Finanznachrichten News

DELRAY BEACH, Fla., Oct. 18, 2024 /PRNewswire/ -- The global Pain Management Devices market is expected to grow to USD 5,835.8 Million by 2029, up from USD 3,768.6 Million in 2024, at a CAGR of 9.1% over the forecast period. Globally, the growing burden of chronic pain conditions, growing number of surgical procedures performed and rising aging population globally are anticipated to accelerate the demand for pain management devices, further propelling the adoption of pain management devices products. Moreover, the growing focus on advanced devices and government initiative to aid affordability and accessibility are likely to fuel the market growth. Moreover, the increasing investments for new product development and growing adoption pain management devices in home care settings owing to its advantages are expected to support the pain management devices market growth during the forecast period.

MarketsandMarkets Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91418163

Browse in-depth TOC on "Pain Management Devices Market"

294 - Tables
64 - Figures
297 - Pages

High procedural cost, and increasing product recalls are likely to hamper the growth of pain management devices market

Based on type, the neurostimulation devices segment held the largest share of of the pain management devices market. Due to the large number of ongoing clinical studies to establish the efficacy and safety of these devices in pain management, new product launches & approvals and the increasing prevalence of chronic pain conditions, among others. In addition, the advantages of neurostimulation as compared to alternative therapies for managing chronic pain are further propelling its market growth.

Based on application, the neuropathic pain segment captured the biggest share in the pain management devices market. This is due to a significant global prevalence of neuropathic pain. The development of new and innovative devices, the presence of substantial clinical evidence bolstering the high efficacy of pain management devices in treating neuropathic pain, the increased incidence of neuropathic pain associated with many age-related diseases, the side effects of medicines used to treat neuropathic pain, and the availability of reimbursement are additional factors driving the adoption of pain management devices for neuropathic pain conditions.

Based on mode of purchase, prescription pain management devices registered the highest share in the pain management device. Due to the availability of a large number of FDA-approved prescription-based pain management devices with established safety and efficacy profiles, long-term cost effectiveness, and favourable reimbursement scenario for these devices compared with OTC devices are driving the growth of this market segment. Also, the rising geriatric population and increasing incidence of diseases conditions such as cancer, diabetes, and arthritis are further boosting the demand for prescription-based pain management devices.

Based on end user, the pain management devices market is segmented into hospitals & clinics , physiotherapy centers , home care settings and others. In 2023, the home care settings segment accounted for the highest growth rate of the pain management devices market while hospitals & clinics segment registered the largest share. Technological advancements in pain management devices and the growing awareness and acceptance of pain management devices (such as disposable pumps) in home care settings to reduce hospital stays, are some of the key factors driving the growth of the home care settings in the pain management devices market.

Based on region, Pain Management Devices market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, North America is expected to register a higher share attributed to the presence of prominent market players, increase in patient population with chronic diseases, increasing healthcare expenditure and rising government efforts to improve the accessibility of pain management devices in the region. While Asia Pacific registers the highest growth rate in coming years due to increase in healthcare expenditure and chronic disease prevalence.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=91418163

Some of the prominent players operating in the market include Medtronic (Ireland), Boston Scientific Corporation(US), Abbott Laboratories (US), Stryker (US), Nevro Corp. (US), Becton, Dickinson and Company (US), Baxter (US), B. Braun SE (Germany), Omron Corporation (Japan), Avanos Medical, Inc. (US), Teleflex Incorporated (US),ICU Medical, Inc. (US), Nipro (Japan), Moog Inc. (US), Atricure, Inc. (US), Micrel Medical Devices SA (Greece), Zynex, Inc.(US), and Enovis Corporation (US).

MEDTRONIC (IRELAND)

Medtronic is the leading key player in the global pain management devices market in 2023. The company's leading position can be attributed to its wide portfolio with a range of advanced solutions including neuromodulation devices, and infusion pumps. The company operates in the US, Europe, and the Asia Pacific. Medtronic's strong market position is bolstered by its commitment to innovation, significant investment in research and development, and adherence to rigorous clinical and regulatory standards, ensuring effective and reliable pain management solutions The company also focuses on organic as well as inorganic growth strategies to gain a competitive edge.

BOSTON SCIENTIFIC CORPORATION (US)

Boston Scientific is a major force in the pain management devices market, distinguished by its advanced spinal cord stimulators and radiofrequency ablation technologies. The company provides neuromodulation products such as rechargeable spinal cord stimulators and microstimulators for managing neuropathic pain. Boston Scientific's geographic presence strategy focuses on global expansion and market adaptation. The company targets major and emerging markets across North America, Europe, Asia-Pacific, and Latin America, customizing its products to meet regional needs and regulatory requirements. Their global network includes state-of-the-art manufacturing and R&D facilities, which facilitate rapid innovation and efficient distribution.

ABBOTT LABORTORIES (US)

Abbott Laboratories is a major player in the market for pain management devices, including cutting-edge neurostimulation and spinal cord stimulation systems. Their Proclaim line of medical devices offers customized treatment plans together with cutting-edge BurstDR technology for improved pain management. Abbott's focus on patient-centered treatment and its commitment to research and development ensure that its products are advanced and highly effective in clinical settings. Abbott continues to be a pioneer in providing reliable and effective pain management devices, with a strong emphasis on stringent clinical trials and regulatory requirements.

For more information, Inquire Now!

Related Reports:

Infusion Pump Market

Ablation Technology Market

Wearable Healthcare Devices Market

Neuromodulation Market

Veterinary Pain Management Market

Get access to the latest updates on Pain Management Devices Companies and Pain Management Devices Market Size

About MarketsandMarkets:

MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pain-management-devices-market-to-hit-usd-5-835-8-million-by-2029-with-9-1-cagr--marketsandmarkets-302280194.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.